271 related articles for article (PubMed ID: 25980593)
1. Lymphangioleiomyomatosis: New Treatment Perspectives.
Radzikowska E
Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
[TBL] [Abstract][Full Text] [Related]
2. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
3. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
4. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Yates DH
Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
6. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatments for lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
Expert Rev Respir Med; 2012 Jun; 6(3):267-76. PubMed ID: 22788941
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
10. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
11. Management of lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
[TBL] [Abstract][Full Text] [Related]
12. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
14. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
15. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
Chebib N; Khouatra C; Lazor R; Archer F; Leroux C; Gamondes D; Thivolet-Bejui F; Cordier JF; Cottin V
Rev Mal Respir; 2016 Oct; 33(8):718-734. PubMed ID: 26604019
[TBL] [Abstract][Full Text] [Related]
16. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
[TBL] [Abstract][Full Text] [Related]
17. Lymphangioleiomyomatosis.
Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
[TBL] [Abstract][Full Text] [Related]
18. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
19. mTOR signaling in lymphangioleiomyomatosis.
Kristof AS
Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic involvement in lymphangioleiomyomatosis.
Glasgow CG; Taveira-Dasilva AM; Darling TN; Moss J
Ann N Y Acad Sci; 2008; 1131():206-14. PubMed ID: 18519973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]